Dercum Disease, Lipedema
Conditions
Brief summary
This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee and men with Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.
Detailed description
This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee and men with Dercum's disease. * The 1st cohort will be comprised of subjects with Dercum's disease. * The 2nd cohort will be comprised of subjects with lipedema with substantial fat above the knee Within each cohort dosing of the subjects will progress consecutively from one individual to the other with a minimum 7 days between subjects to asses safety. The study design will allow the physicians to monitor safety for at least 7 days prior to dosing the next subject. Cohort 2 will be conducted in a dose escalation manner and the decision to proceed to the next dose level will be made after reviewing all safety data collected by Day 14 within 2+/-1 day of the last dosed subject. The trial will proceed within a cohort provided that no more than one subject experience intolerable side effects in a cohort, and based on the decision made by the Principal Investigator (PI) and the medical monitor.
Interventions
DRUGRZL-012
The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
Sponsors
University of Arizona
Raziel Therapeutics Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Post-menopausal (at least 2 years) women no more than 65 years old, with lipedema involving substantial fat above the knee or nodular Dercum's disease in such women and in men 20 - 65 years with nodular Dercum's disease. 2. For Dercum's disease subjects - at least 2 nodules to be injected of at least 2cm diameter each, as determined by ultrasound 3. For lipedema subjects - Significant subcutaneous fat above the knee as determined by circumference of 50cm 4. Generally considered healthy according to medical history, physical examination, ECG and laboratory evaluation with a special emphasis on metabolic parameters (fasting glucose concentration \< 100 mg, normal blood pressure). 5. Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study. 6. Subjects must sign an informed consent indicating that they are aware of the investigational nature of the study.
Exclusion criteria
1. Unable to tolerate subcutaneous injection. 2. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that in the opinion of the investigator, put the subject at significant risk, are not eligible. 3. Positive blood screen for Hepatitis B surface antigen (HbSAg), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV), or positive urine screen for alcohol or drugs of abuse (unless prescribed by a physician). 4. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune disease or subjects taking immunosuppressive drugs such as corticosteroids are ineligible. 5. As a result of medical review, physical examination, the PI (or medically qualified nominee) considers the subject unfit for the study. 6. Known sensitivity to components of the injection formulation. 7. Prior wound, tattoo or infection in the treated area. 8. Prior invasive treatment such as surgery or injectable drug at the RZL-012 injected area.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | 0-14 days | Trial will proceed as long as no more than one subject experiences an intolerable side effect in a cohort |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 - Dercum's Disease Nodular size - diameter (cm) 2-2.9, 3-3.9, 4-8 Total dose of RZL-012(mg) 10 15 20 Dose per NOAEL 1/25th , 1/18.75th, 1/12.5th Number of injections: 2,3,4
RZL-012: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites | 6 |
| Cohort 2 - Lipedema 60mg Total dose of RZL-012 (mg) 60 Number of injections: 12
RZL-012: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites | 3 |
| Cohort 2 - Lipedema 80mg Total dose of RZL-012 (mg) 80 Number of injections: 16
RZL-012: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites | 3 |
| Total | 12 |
Baseline characteristics
| Characteristic | Cohort 1 - Dercum's Disease | Total | Cohort 2 - Lipedema 80mg | Cohort 2 - Lipedema 60mg |
|---|---|---|---|---|
| Age, Continuous | 57.3 Years STANDARD_DEVIATION 6.3 | 57.3 Years STANDARD_DEVIATION 5.4 | 57.3 Years STANDARD_DEVIATION 5 | 57.3 Years STANDARD_DEVIATION 5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 11 Participants | 3 Participants | 3 Participants |
| Region of Enrollment United States | 6 participants | 12 participants | 3 participants | 3 participants |
| Sex: Female, Male Female | 1 Participants | 7 Participants | 3 Participants | 3 Participants |
| Sex: Female, Male Male | 5 Participants | 5 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 3 | 0 / 3 |
| other Total, other adverse events | 6 / 6 | 3 / 3 | 3 / 3 |
| serious Total, serious adverse events | 0 / 6 | 0 / 3 | 0 / 3 |
Outcome results
Primary
The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort
Trial will proceed as long as no more than one subject experiences an intolerable side effect in a cohort
Time frame: 0-14 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 - Dercum's Disease | The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | 0 Participants |
| Cohort 2 - Lipedema 60mg | The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | 0 Participants |
| Cohort 2 Lipedema 80mg | The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort | 0 Participants |